乐虎国际娛乐

English
banner
Products
Home

Pharmaceutical Intermediates

NIFURATEL INTERMEDIATE 14359-97-8

NIFURATEL INTERMEDIATE 14359-97-8

99% up, Medical Grade
  • Product Details

Product Information


Product name

Nifuratel Intermediate 14359-97-8

1-hydrazino-3-(methylthio)-2-propanol

Molecular Formula

C4H12N2OS

Molecular Weight

136.22

CAS No.

14359-97-8

Quality Standard

99% up by HPLC, medical grade

Appearance

White powder


COA of Nifuratel Intermediate 40371-50-4


ITEMS

STANDARDS

RESULTS

Appearance

Clear or Yellowish Oily Liquid

Conforms

Identification

HPLC Retention Time

Consistence with Standard

Conforms

Water content (by GC)

≤1.0%

0.09%

Purity (By GC, Area%)

≥85.0%

88.4%

Conclusion

Compiles with I.H.S.


Usage


1-hydrazino-3-(methylthio)-2-propanol with its CAS No.: 14359-97-8 is a key intermediate of Nifuratel. Nifuratel indications for the treatment of vulvar, vaginal infections and vaginal discharge and urinary tract infections caused by bacteria, trichomoniasis, mold and candida, digestive amebiasis and giardiasis.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

CBZ-L-HABA
AMIKACIN INTERMEDIATE 40371-50-4 CBZ-L-HABA
99% up by HPLC, medical grade
TELMISARTAN INTERMEDIATE
TELMISARTAN INTERMEDIATE 152628-03-0
99% up, Medical Grade
NITROBENZALDEHYDE
M-NITROBENZALDEHYDE 99-61-6
99% up, Medical Grade
LIRAGLUTIDE
LIRAGLUTIDE 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
AZILSARTAN
AZILSARTAN 147403-03-0
99% up, JP/ GMP / PMDA / DMF
PALMITOYLETHANOLAMIDE
PALMITOYLETHANOLAMIDE (PEA) 544-31-0
Product Information Product name Palmitoylethanolamide (PEA) Molecular Formula C18H37NO2 CAS No. 544-31-0 Quality Standard 98% up(Micronized Grade), Food grade, Cosmetic grade Appearance White powder COA of Palmitoylethanolamide (PEA) Testing Items Specifications Results Appearance Fine Powder Compiles Color White to Off-white Compiles Identification Positive Compiles Heavy Metals NMT 10 ppm Compiles Arsenic(As2O3) NMT 1 ppm Compiles Sulfate(SO4) NMT 0.040% Compiles Iron(Fe) NMT 10 ppm Compiles Chloride(Cl) NMT 0.020% Compiles Solvent Residual Meeting USP Standard Compiles Total Plate Count 10,000 cfu/g Max Compiles Yeast & Mold 300 cfu/g Max Compiles Coliforms 10 cfu/g Max Compiles E. Coli Negative/ 10g Negative Salmonella sp. Negative/ 25g Negative Staph Aureus Negative/ 10g Negative Pseudomonas Negative/ 25g Negative Residue on ignition 0.1% Max 0.03% Particle size D(0.5): 3um D(0.569): 3um D(0.99): 10um D(0.995): 10um Excipients None Confirm Loss on Drying 1.0% Max 0.15% Assay (on dried base, GC) NLT 98% 98.75% Conclusion The product conforms to in-house standard Usage Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, belonging to the class of nuclear factor agonists. PEA is one of the most important endogenous painkilling and anti-inflammatory compounds and has been shown to effective for both acute and chronic pain. Because the substance acts as a natural painkiller, it is an excellent alternative for conventional medications that might cause side effects. Function: 1. Anti-Inflammatory and Analgesic 2. Improve the ability of immunity 3. Treated chronic pain 4. Treated epilepsy, cerebral ischemia and stroke 5. Treated Alzheimer's disease and Parkinson's disease
ALPHA GPC
ALPHA GPC 28319-77-9
99% up, Food Grade
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

home

products

about

contact

乐优彩票登入,备用,官方网址 乐优彩票天天红单下载 乐优彩票网址是多少 乐优炫彩app 乐优炫彩app下载 乐博彩票官方app 乐优炫彩官网 乐优炫彩彩票app下载 乐体育app下载 乐善彩票网址